The use of immunophenotyping to assess minimal residual disease (MRD) in multiple myeloma
How important is understanding the tumour microenvironment in treating CLL?
Exploiting signalling pathways involved in CLL to develop novel therapies
What is the rationale for novel combination therapies?
Niels van de Donk
From the microenvironment to the CLL patient